- Notable Two Hundred Day Moving Average Cross - ZBH
Sep 15, 2025
In trading on Monday, shares of Zimmer Biomet Holdings Inc (Symbol: ZBH) crossed below their 200 day moving average of $101.89, changing hands as low as $100.77 per share. Zimmer Biomet Holdings Inc shares are currently trading off about 2.2% on the day. The chart below shows the one year performance of ZBH shares, versus its 200 day moving average:
Looking at the chart above, ZBH's low point in its 52 week range is $89.24 per share, with $114.72 as the 52 week high point — that compares with a last trade of $100.96. The ZBH DMA information above was sourced from TechnicalAnalysisChannel.comFree Report: Top 8%+ Dividends (paid monthly)
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
Also see: Top Ten Hedge Funds Holding ABMD
HASI Dividend History
Top Ten Hedge Funds Holding FUTS
</p>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Cell Cryopreservation Market Size to Expand USD 77.52 Bn by 21.05% CAGR till 2034
Aug 25, 2025
Ottawa, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Towards Healthcare, a sister firm of Precedence Research, reports that the global cell cryopreservation market reached USD 11.48 billion in 2024 and is projected to grow to approximately USD 77.52 billion by 2034, expanding at a CAGR of 21.05%.
The growth is driven by the increasing demand for personalized therapy, rising infertility rates, regenerative medicine, and technological advancement fuel the growth of the market.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5361
Key Takeaways
North America dominated the cell cryopreservation market share by 41%.Asia Pacific is estimated to grow at the fastest rate during the forecast period.By product, the consumables segment dominated the cell cryopreservation market in 2023.By product, the freezing media segment is estimated to witness the fastest CAGR in the cell cryopreservation market during the forecast period of 2024-2034.By application, the stem cells segment held the major share of the cell cryopreservation market in 2023.By application, the oocytes and embryonic cells segment is estimated to grow at the fastest rate in the cell cryopreservation market during the predicted timeframe.By end-use, the IVF clinics segment held the largest share of the cell cryopreservation market in 2023.By end-use, the biobanks segment is expected to achieve the fastest CAGR in the cell cryopreservation market during the forecast period.
Market Overview & Potential
Preserving living cells and tissues at extremely low temperatures, typically with liquid nitrogen (-196°C), is known as cryopreservation. This method allows for long-term storage of biological materials, preventing them from degrading and maintaining their function. To protect cells from damage during freezing and thawing, chemicals like DMSO or glycerol are added to the cell suspension. These chemicals help reduce ice crystal formation. Cells are then cooled at a controlled rate, usually with a programmable freezer or specialized container, to minimize damage. Once frozen, cells are stored in liquid nitrogen for long-term preservation. When needed, cells are quickly thawed to reduce exposure to potentially damaging conditions.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What is the Growth Potential Responsible for The Growth of The Cell Cryopreservation Market?
The growth of the market is driven by the growing demand for personalized therapy and regenerative medicine, which are tailored according to the individual patients which making cryopreservation crucial, fueling the growth of the market. The rising infertility rates, which demand egg and sperm cryopreservation, also influence the demand for the market, driving growth. The technological advancement, like improved cryopreservation techniques and enhanced cell storage and thawing this leads to better and efficient treatment outcomes, fueling the growth and expansion of the market. Other key drivers are rising chronic diseases, government initiatives, organ transplantation, and clinical trials.
What Are the Growing Trends Associated with the Cell Cryopreservation Market?
Stem Cell Banking And Regenerative Medicine
The increasing use of stem cells in the treatment of various diseases is a growing trend used in regenerative medicine and therapies.
Fertility Preservation
The growing demand for reproductive use is a growing trend that contributes to the growth of the market.
Biobanking Initiatives
Investments in large-scale biorepositories fuel the growth and demand for the market.
Automation In Cryopreservation
Integration of automation in the system for enhancing efficiency, sample security, and accuracy fuels the growth of the market.
What Is the Growing Challenge in the Cell Cryopreservation Market?
The key challenge that hinders the growth of the market are cryoinjury and cell damage, compatibility and standardization, long-term storage limitation, regulatory compliance, cost and accessibility, ethical and legal considerations, high initial and operational costs, and market competition limit the growth and expansion of the market.
Regional Analysis
How Did North America Dominate the Cell Cryopreservation Market in 2024?
The North America growth of the cell cryopreservation market is driven by 41% share. The high prevalence of chronic diseases in the region fuels the growth of the market. The other key growth drivers of the market in the region are advanced healthcare infrastructure, research and development investments, government initiatives, rising adoption of personalized medicine, and increased demand for regenerative medicine boost the growth of the market in the region. The key players like BioLife Solutions, Corning, and Thermo Fisher Scientific play a crucial role in the growth and expansion of the market.
What Made the Asia Pacific Significantly Grow in The Cell Cryopreservation Market In 2024?
The growth of the market in the Asia Pacific is driven by various factors, like A growing population, rising healthcare costs, improvements in healthcare infrastructure, and increasing incidence of chronic diseases are major growth drivers. The major drivers are the government support and initiatives for the promotion of biotechnology and life sciences research contribute to the growth of the market. The key players like Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, and Lonza Group Ltd. also play a significant role in the growth, though innovation and cell therapy solutions further fuel the growth and expansion of the market.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
Segmental Insights
By product,
Which Product Segment Dominated The Cell Cryopreservation Market In 2024?
The consumables segment dominated the cell cryopreservation market in 2023. Consumables play a crucial role in the cell cryopreservation market as they are required for routine storage and preservation processes. These include cryovials, cryobags, pipettes, and related supplies that ensure sterile handling and safe freezing of biological materials. Their consistent demand from research institutes, biobanks, and IVF clinics drives their growth, as they are indispensable for maintaining sample quality across multiple applications.
The freezing media segment is estimated to witness the fastest CAGR in the cell cryopreservation market during the forecast period of 2024-2034. Freezing media is a vital product segment, formulated to protect cells, tissues, and reproductive materials from damage during ultra-low temperature storage. These specialized media typically contain cryoprotectants that minimize ice crystal formation and preserve cell integrity. Increasing adoption of freezing media in stem cell research, regenerative medicine, and fertility treatments highlights their essential role in ensuring higher cell survival rates post-thaw.
By application,
How Did Stem Cells Segment Dominate The Cell Cryopreservation Market In 2024?
The stem cells segment held the major share of the cell cryopreservation market in 2023. Stem cells are a primary application area for cell cryopreservation, given their importance in regenerative medicine, personalized therapies, and drug discovery. Effective freezing and long-term storage of stem cells are crucial to maintaining their viability and therapeutic potential. Growing investments in stem cell banking and the rising use of stem cells in advanced clinical research further enhance demand within this segment.
The oocytes and embryonic cells segment is estimated to grow at the fastest rate in the cell cryopreservation market during the predicted timeframe. Oocytes and embryonic cells represent a significant application segment, driven by the rising prevalence of fertility treatments and IVF procedures. Cryopreservation enables the long-term storage of reproductive cells while maintaining their viability, which is critical for assisted reproduction technologies. Increasing global awareness of fertility preservation options and expanding IVF clinic networks strengthen the growth of this application.
By end-use,
How did IVF Clinics dominate the Cell Cryopreservation Market in 2024?
The IVF clinics segment held the largest share of the cell cryopreservation market in 2023. IVF clinics account for a substantial share of the cell cryopreservation market as they rely on advanced preservation techniques for reproductive cells and embryos. Cryopreservation supports treatment flexibility and improved success rates, making it integral to modern fertility care. With the growing demand for assisted reproductive technologies, IVF clinics continue to be a key end-user segment.
By end-use, the biobanks segment is expected to achieve the fastest CAGR in the cell cryopreservation market during the forecast period. Biobanks are a critical end-user segment, serving as repositories for a wide range of biological samples, including stem cells, tissues, and genetic material. These facilities require large-scale cryopreservation systems and consumables to ensure long-term sample integrity for research and therapeutic use. The expansion of personalized medicine and genetic research further fuels the reliance of biobanks on cryopreservation solutions.
Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Recent Developments
In September 2024, the novel aseptic micro-connector produced by CPC (Colder Products Company), a division of Dover, is designed to slot straight into the frozen cassettes used in the processing of cell and gene therapy (CGT). Cryopreservation, which involves freezing CGT biological materials at extremely low temperatures, reduces material loss of function that happens during product storage and transportation, which takes place before patient therapy delivery.
In October 2024, according to David Sheehan, CEO of Nucleus Biologics, the introduction of NB-KUL DF ushers in a new era in the cryopreservation of cells employed for therapeutic purposes. This solution will remove negative effects for patients while lowering complexity and expense.
Cell Cryopreservation Market Key Players
Thermo Fisher Scientific Inc.Merck KGaASartorius AGPromoCell GmbHLonzaHiMedia LaboratoriesCreative BiolabsCorning IncorporatedBioLife Solutions Inc.
Browse More Insights of Towards Healthcare:
The global autologous cell therapy market is valued at USD 9.6 billion in 2024 and is expected to grow to USD 11.41 billion in 2025. By 2034, the market is projected to reach approximately USD 54.21 billion, expanding at a CAGR of 18.9% between 2025 and 2034.
The global autologous stem cell and non-stem cell therapies market is estimated at USD 5.15 billion in 2024 and is anticipated to rise to USD 6.81 billion in 2025. Over the forecast period, it is expected to surge to around USD 82.32 billion by 2034, growing at an impressive CAGR of 32.26%.
The global single cell sequencing market started at USD 1.63 billion in 2024 and is projected to reach USD 1.88 billion in 2025. By 2034, the market is expected to surpass USD 6.65 billion, achieving a steady CAGR of 15.05%.
The global cellular immunotherapy market recorded USD 11.33 billion in 2024, is set to reach USD 13.87 billion in 2025, and is projected to hit nearly USD 85.78 billion by 2034, expanding at a CAGR of 22.45% throughout the forecast period.
The global cell and gene therapy clinical trials market reached USD 10.8 billion in 2024, is expected to grow to USD 12.47 billion in 2025, and is projected to attain around USD 45.31 billion by 2034, expanding at a CAGR of 15.43%.
The global cell-based assays market began at USD 17.29 billion in 2024 and is forecast to rise to USD 18.82 billion in 2025. By the end of 2034, it is expected to exceed USD 39.92 billion, growing at a CAGR of 8.84%.
The global cell and gene solutions market is on a strong upward trajectory, with potential revenues expected to climb significantly over the forecast period from 2025 to 2034.
The global cell-based immunotherapies market is valued at USD 4.59 billion in 2024, expected to reach USD 5.28 billion in 2025, and is projected to grow to approximately USD 18.62 billion by 2034, at a CAGR of 15.02%.
The global cell banking outsourcing market is calculated at USD 14.37 billion in 2024, projected to rise to USD 16.72 billion in 2025, and expected to reach around USD 63.49 billion by 2034, growing at a CAGR of 16.37%.
The global host cell protein testing market is estimated at USD 2.37 billion in 2024, anticipated to grow to USD 2.56 billion in 2025, and projected to reach approximately USD 5.19 billion by 2034, expanding at a CAGR of 8.17%.
Segments Covered in The Report
By Product
Consumables
Cryogenic VialsCryogenic TubesCooler Boxes/ContainersOthersCell Freezing Media
Ethylene GlycolDimethyl SulfoxideGlycerolOthersEquipment
FreezersIncubatorsLiquid Nitrogen Supply Tanks
By Application
Stem CellsOocytes and Embryonic CellsSperm CellsHepatocytesOthers
By End-use
IVF ClinicsBiobanksBiopharmaceutical & Pharmaceutical CompaniesResearch InstitutesOthers
By Region
North America
U.S.CanadaAsia Pacific
ChinaJapanIndiaSouth KoreaThailandEurope
GermanyUKFranceItalySpainSwedenDenmarkNorwayLatin America
BrazilMexicoArgentinaMiddle East and Africa (MEA)
South AfricaUAESaudi ArabiaKuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5361
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive |Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods |Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
- Edge expands distribution partnership with ABMDA across US and Canada
Aug 15, 2025
GRAND RAPIDS, Mich. - Edge, a manufacturer of exterior trim, siding, and interior accents, announced Wednesday an expansion of its partnership with Associated Building Material Distributors of America, Inc. (ABMDA) to increase its distribution network throughout the United States and Canada. The expansion comes as parent company UFP Industries (NASDAQ:UFPI), a $6 billion market cap building products manufacturer, maintains strong financial health with more cash than debt on its balance sheet, according to InvestingPro data.
The expanded partnership marks Edge’s entry into Canadian markets while strengthening its U.S. presence. The collaboration will focus on distributing Edge’s product lines including EvoTrim, ForgeWood thermally modified siding, and the Timeless line of interior accent boards.
"ABMDA’s strong presence in the market coupled with their dedication to excellence makes them an invaluable partner," said Dom Beaulieu, Managing Director of Edge, according to the press release.
Brendan Moloney, Director of Sales for Edge, noted the "powerful synergies" between the two organizations in terms of values and practices.
The rollout of Edge products to ABMDA member distributors is scheduled to continue through the end of 2025. The partnership aims to leverage ABMDA’s regional expertise to enhance support for builders seeking Edge’s product offerings.
Edge is a brand of UFP Retail Solutions, a business segment of UFP Industries (NASDAQ:UFPI), which is headquartered in Grand Rapids, Michigan, with facilities across North America, Australia, Europe, and Asia.
The information in this article is based on a company press release statement.
In other recent news, UFP Industries reported its second-quarter earnings for 2025, which did not meet analysts’ expectations. The company announced an earnings per share (EPS) of $1.70, falling short of the projected $1.86. Additionally, revenue was slightly below forecasts, coming in at $1.84 billion compared to the anticipated $1.85 billion. DA Davidson maintained its Neutral rating on Universal Forest Products, holding the price target at $110. The firm noted that the company’s performance was weaker than expected, primarily due to lower-than-expected Retail volume and gross margin. DA Davidson attributed some of the challenges to immediate headwinds from certain shelf-space losses. The anticipated benefits from shelf-space gains have been slower to materialize, according to the firm. These developments highlight recent challenges faced by UFP Industries.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
- Edge Expands Partnership with ABMDA, Entering New Markets
Aug 15, 2025
Both Look Forward to Meeting Builder Demands with Best-In-Class Products and Distribution
GRAND RAPIDS, Mich., August 15, 2025--(BUSINESS WIRE)--Edge, manufacturer of advanced exterior trim, siding, and interior accents, has announced an expansion of its partnership with Associated Building Material Distributors of America, Inc. (ABMDA), growing its footprint of distribution partners throughout the United States and Canada. In addition to bolstering availability in the US, this represents the brand’s entrance into Canadian markets. With the regional and distribution expertise of ABMDA members, builders will enjoy enhanced support of Edge’s leading product lines, including treated wood EvoTrim™, the new thermally modified siding line, ForgeWood, and upcoming innovations from the brand.
Dom Beaulieu, Managing Director of Edge, emphasized the significance of this announcement, saying, "ABMDA’s strong presence in the market coupled with their dedication to excellence makes them an invaluable partner. This expansion enables us to deliver our high-performing products to a broader audience and provide additional value to our customers by addressing the demand for both service and quality."
Added Brendan Moloney, Director of Sales for Edge, "We’ve seen powerful synergies between ABMDA and Edge so far in the values and practices of both organizations. We look forward to further strengthening our ties with its distributor members in the coming months."
Garry Tabor, Executive Vice President of ABMDA commented, "Our strong relationships with suppliers provide our members with the products and services that help our customers stand out, and we’re excited to add Edge as a partner that is committed to delivering superior solutions."
Edge products, namely EvoTrim, ForgeWood, and the Timeless line of ultra-smooth interior accent boards, are rolling out to ABMDA member distributors through the end of 2025. To learn more about the full product offering, visit ufpEDGE.com.
About Edge
Edge is a leading provider of trim, siding, and interior accents. Its product lines include prefinished and natural solutions such as ForgeWood thermally modified siding, the Timeless interior accent board collection, and primed, exterior-rated trim lines EvoTrim™, Premium Primed, and Primed SPF. Sourced and manufactured in North America, its high quality, convenient, and beautiful products make Edge a valued provider to building materials distributors and retailers nationwide. Edge is a brand of UFP Retail Solutions, a business segment of UFP Industries.
Story Continues
Headquartered in Grand Rapids, Mich., with facilities throughout North America, Australia, Europe, and Asia, UFP Industries, Inc. (Nasdaq: UFPI) is a holding company whose affiliates serve the retail, construction, and industrial markets. Those affiliates are strategically positioned to deliver a wide variety of products to nationwide retailers that cater to both consumers and building professionals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806554026/en/
Contacts
Serena.Bonarski@ufpi.com
View Comments
- IoMT Wearable Devices Patent Landscape Report and Forecasts, 2017-2023 & 2024-2032 Featuring Veniam, Advanced Neuromodulation Systems, Bionet Sonar, and Abiomed
Mar 4, 2025 · globenewswire.com
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "IoMT Wearable Devices Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The IoMT wearable devices market was valued at USD 34.93 billion in 2023. It is expected to grow at a CAGR of 23.0% during the forecast period of 2024-2032 and attain a market value of USD 225.1 billion in 2032. The patent landscape is driven by advancements in sensor technology, AI integration, and connectivity solutions, enhancing diagnostic accuracy and personalised treatment. The global IoMT wearable devices patent landscape report offers an in-depth analysis of the dynamic patent environment. It explores innovations in sensor technologies, AI integration, and advanced connectivity solutions that are shaping the future of IoMT wearables. The report provides detailed segmentation by product type, modality, and application, highlighting key patents and emerging trends.
- IOMT WEARABLE DEVICES PATENT LANDSCAPE REPORT AND FORECASTS, 2017-2023 & 2024-2032 FEATURING VENIAM, ADVANCED NEUROMODULATION SYSTEMS, BIONET SONAR, AND ABIOMED
Mar 4, 2025
DUBLIN, MARCH 04, 2025 (GLOBE NEWSWIRE) -- THE "IOMT WEARABLE DEVICES PATENT LANDSCAPE REPORT AND FORECAST 2024-2032" REPORT HAS BEEN ADDED TO RESEARCHANDMARKETS.COM'S OFFERING. THE IOMT WEARABLE DEVICES MARKET WAS VALUED AT USD 34.93 BILLION IN 2023. IT IS EXPECTED TO GROW AT A CAGR OF 23.0% DURING THE FORECAST PERIOD OF 2024-2032 AND ATTAIN A MARKET VALUE OF USD 225.1 BILLION IN 2032. THE PATENT LANDSCAPE IS DRIVEN BY ADVANCEMENTS IN SENSOR TECHNOLOGY, AI INTEGRATION, AND CONNECTIVITY SOLUTIONS, ENHANCING DIAGNOSTIC ACCURACY AND PERSONALISED TREATMENT. THE GLOBAL IOMT WEARABLE DEVICES PATENT LANDSCAPE REPORT OFFERS AN IN-DEPTH ANALYSIS OF THE DYNAMIC PATENT ENVIRONMENT. IT EXPLORES INNOVATIONS IN SENSOR TECHNOLOGIES, AI INTEGRATION, AND ADVANCED CONNECTIVITY SOLUTIONS THAT ARE SHAPING THE FUTURE OF IOMT WEARABLES. THE REPORT PROVIDES DETAILED SEGMENTATION BY PRODUCT TYPE, MODALITY, AND APPLICATION, HIGHLIGHTING KEY PATENTS AND EMERGING TRENDS.
- US FDA classifies recall of Abiomed's blood pumps as most serious
Mar 21, 2024 · reuters.com
The U.S. health regulator on Thursday classified the recall of blood pumps by Abiomed, a Johnson & Johnson company, as the most serious and said their use could cause serious injuries or death.
- 14 Best Dividend Stocks To Buy and Hold
Jan 18, 2023
In this article, we discuss 14 best dividend stocks to buy and hold. If you want to see more stocks in this selection, check out 5 Best Dividend Stocks To Buy and Hold.
Despite a slowing economy, investors remain confident in dividend growth to cushion their portfolios from financial blows in terms of eroding share prices. Alec Young, chief investment strategist at MAPsignals, told BNN Bloomberg in the beginning of January 2023 that dividend stocks are not only a source of passive income in a volatile environment, but these equities have also contributed about 40% to the overall performance of the US stock market. He noted that data suggests dividend stocks are the best performers during periods of peak inflation, which is the current case for the United States, with CPI inflation between 6% and 7%. Dividend stocks outperform non-dividend payers by a significant margin in times of economic turbulence, as per Young.
Similarly, Todd Rosenbluth, head of research at VettaFi, anticipates dividend ETFs to be favored this year. He appreciates the Vanguard High Dividend Yield Index Fund (NYSE:VYM), which has companies with above-average dividend yields and provides exposure to defensive sectors. For tech exposure, Rosenbluth recommends the ALPS Sector Dividend Dogs ETF (NYSE:SDOG), a fund that has the five highest-yielding S&P 500 stocks across 10 sectors, with equal weight holdings.
For more insights into dividend equities, investors can also check out 11 Undervalued Dividend Aristocrats to Buy, 12 Cheap Monthly Dividend Stocks To Buy, and 11 Best Dividend Stocks Yielding Over 6%. Some of the best dividend stocks to consider include The Home Depot, Inc. (NYSE:HD), Mastercard Incorporated (NYSE:MA), and UnitedHealth Group Incorporated (NYSE:UNH).
Our Methodology
We scanned Insider Monkey’s database of holdings of 920 elite hedge funds tracked as of the end of the third quarter of 2022 and picked the top 14 stocks that have been raising their dividends consistently for the past several years and offer stability in terms of business and cash position. The list is arranged in ascending order of the number of hedge fund holders in each firm.
Story continues 14 Best Dividend Stocks To Buy and Hold
Photo by NeONBRAND on Unsplash
Best Dividend Stocks To Buy and Hold
14. McDonald's Corporation (NYSE:MCD)
Number of Hedge Fund Holders: 53
Dividend Yield as of January 17: 2.26%
McDonald's Corporation (NYSE:MCD) operates and franchises McDonald's restaurants in the United States and internationally. It is one of the best dividend stocks to buy and hold, as McDonald's Corporation (NYSE:MCD) has increased its dividend for 46 consecutive years. On December 15, McDonald's and five of its suppliers signed a deal to purchase about 190 megawatts of power from Blue Jay Solar Farm. McDonald's aims to cut greenhouse emissions by 36% by 2030 and become net zero by 2050.
On January 13, Loop Capital analyst Alton Stump kept a Buy rating and a $328 price target on McDonald's Corporation (NYSE:MCD) but noted that his latest franchisee checks indicate same-store sales growth was greater than expectations in Q4. Same-store sales were up 7.0%-7.5% in December and increased 8.5-9.0% for the fourth quarter, ahead of his last estimate for 8.0% growth and consensus of more than 8.1%, the analyst wrote in a research note.
According to Insider Monkey’s data, McDonald's Corporation (NYSE:MCD) was part of 53 hedge fund portfolios at the end of September 2022, compared to 50 funds in the last quarter. Ray Dalio’s Bridgewater Associates is the biggest stakeholder of the company, with 2.11 million shares worth $487.7 million.
In addition to The Home Depot, Inc. (NYSE:HD), Mastercard Incorporated (NYSE:MA), and UnitedHealth Group Incorporated (NYSE:UNH), McDonald's Corporation (NYSE:MCD) is one of the best dividend stocks to buy and hold.
13. The Coca-Cola Company (NYSE:KO)
Number of Hedge Fund Holders: 59
Dividend Yield as of January 17: 2.87%
The Coca-Cola Company (NYSE:KO) is one of the best dividend stocks to invest in. It is a reliable dividend king, and the company will announce its 61st consecutive dividend increase on February 16th, 2023. The Coca-Cola Company (NYSE:KO) reported on November 30 that it has slashed the number of brands in its portfolio to 200 from 400, while doubling down on scaled global bets to provide beverages across different categories, including alcohol.
On December 20, Atlantic Equities analyst Edward Lewis said he anticipates a more constrained environment for the global consumer in FY23 as input costs remain high and companies will be looking to at least hold if not hike prices in some cases. In this context, The Coca-Cola Company (NYSE:KO) is one of his preferred names in beverages, as he sees category momentum, continuous investment, and robust execution driving elevated growth. The analyst has an Overweight rating on The Coca-Cola Company (NYSE:KO) shares with a $69 price target.
According to Insider Monkey’s data, 59 hedge funds were bullish on The Coca-Cola Company (NYSE:KO) at the end of Q3 2022, compared to 60 funds in the last quarter. Warren Buffett’s Berkshire Hathaway is the biggest stakeholder of the company, with 400 million shares worth $22.40 billion.
In its Q2 2022 investor letter, ClearBridge Investments, an asset management firm, highlighted a few stocks and The Coca-Cola Company (NYSE:KO) was one of them. Here is what the fund said:
“Over the last year, we have repositioned our portfolio to navigate the course we see ahead. We added to more defensive areas of the portfolio like consumer staples (The Coca-Cola Company (NYSE:KO)). While the next month or two will likely prove choppy on account of the Omicron variant, we believe that Omicron, like Delta, represents a speed bump on the way to recovery rather than a true change in course. We see strong economic momentum continuing in 2022 and we expect interest rates to rise. After a decade of remarkably low rates, we would not be surprised if this change in direction is accompanied by some fits and starts in the markets. With our emphasis on pricing power, purposeful sector exposure, valuation discipline, and a strong dividend profile, we believe we are well-positioned for the year ahead.”
12. Walmart Inc. (NYSE:WMT)
Number of Hedge Fund Holders: 68
Dividend Yield as of January 17: 1.54%
Walmart Inc. (NYSE:WMT) engages in the operation of retail and wholesale units worldwide. The company operates through three segments – Walmart U.S., Walmart International, and Sam's Club. On January 5, Walmart Inc. (NYSE:WMT) announced that it completed over 6,000 drone deliveries during the year from its 36 drone delivery hubs across seven states. As of the end of 2022, locations in Arizona, Arkansas, Florida, North Carolina, Texas, Utah and Virginia offered drone delivery. The company is looking to expand its delivery radius in 2023. Walmart Inc. (NYSE:WMT) is one of the leading dividend stocks to invest in, with 50 years of consecutive dividend increases under its belt.
On December 19, Credit Suisse analyst Karen Short assigned Walmart Inc. (NYSE:WMT) an Outperform rating with a price target of $170, citing the company's recent market share gains and positioning as a defensive name in an uncertain macroeconomic environment.
According to Insider Monkey’s third quarter database, 68 hedge funds were long Walmart Inc. (NYSE:WMT), compared to 67 funds in the prior quarter. Ken Fisher’s Fisher Asset Management is the leading stakeholder of the company, with 8.12 million shares worth $1.05 billion.
In its Q2 2021 investor letter, ClearBridge Investments, an asset management firm, highlighted a few stocks and Walmart Inc. (NYSE:WMT) was one of them. Here is what the fund said:
“The pandemic has created challenges for businesses large and small; one major challenge for large essential retailers such as ClearBridge holdings Home Depot, Walmart Inc. (NYSE:WMT) and Costco have been ensuring adequate staffing to meet demand under trying conditions. All three instituted enhanced pay practices during the pandemic, with raises, unplanned bonuses and other benefits helping compensate employees for their efforts in a difficult environment. In September 2020 Walmart raised wages for 165,000 employees, including a number of entry positions to $15 an hour. It followed this in February with a raise for 425,000 workers that moved its average pay above $15 an hour.”
11. Costco Wholesale Corporation (NASDAQ:COST)
Number of Hedge Fund Holders: 69
Dividend Yield as of January 17: 0.74%
Costco Wholesale Corporation (NASDAQ:COST) engages in the operation of membership warehouses in the United States, Puerto Rico, Canada, the United Kingdom, Mexico, Japan, Korea, Australia, Spain, France, Iceland, China, and Taiwan. Costco Wholesale Corporation (NASDAQ:COST) has raised its quarterly dividends for 18 consecutive years, and the dividend growth outlook remains robust.
On January 5, Costco Wholesale Corporation (NASDAQ:COST) reported December sales of $23.80 billion, up 7% from $22.24 billion last year. The company posted net sales of $82.16 billion for the 18 weeks ended January 1, 2023, compared to $76.34 billion in the same period last year. It is one of the best dividend stocks to buy and hold.
DA Davidson analyst Michael Baker on January 6 raised the price target on Costco Wholesale Corporation (NASDAQ:COST) to $478 from $470 and maintained a Neutral rating on the shares. This is based on the company's December sales data, which showed improved comps in the five weeks ending January 1. The analyst noted that Costco Wholesale Corporation (NASDAQ:COST) is the first major retailer to indicate a sales recovery compared to November, and the December comps are optimistic not only for Costco but for the short-term retail industry in general.
According to Insider Monkey’s data, 69 hedge funds were long Costco Wholesale Corporation (NASDAQ:COST) at the end of Q3 2022, compared to 64 funds in the last quarter. Ken Fisher’s Fisher Asset Management is the biggest stakeholder of the company, with 2.5 million shares worth $1.20 billion.
Rowan Street Capital made the following comment about Costco Wholesale Corporation (NASDAQ:COST) in its Q4 2022 investor letter:
“Let’s look at Costco Wholesale Corporation (NASDAQ:COST). Its dividend yield is 0.8%. Earnings over the next 3-5 years are forecasted to grow at ~10%. The current P/E multiple is a very pricey 34x for such growth rate. Now, Costco is an outstanding business with consistent profits and cash flows. However, the price that you pay is important (and you tend to pay a very high price for a “cheery consensus”) and if the earnings multiple comes down to say 30x, you internal rate of return (IRR) over the next 4-5 years will be around 6-7% from holding Costco’s stock. It's a decent market-like return, but nothing to be excited about (only a few percentage points over risk-free rate).”
10. Broadcom Inc. (NASDAQ:AVGO)
Number of Hedge Fund Holders: 74
Dividend Yield as of January 17: 3.18%
Broadcom Inc. (NASDAQ:AVGO) is a California-based company that designs, develops, and supplies various semiconductor devices worldwide. On December 8, Broadcom Inc. (NASDAQ:AVGO) reported earnings for FQ4 2022, disclosing non-GAAP earnings per share of $10.45, beating market estimates by $0.17. The revenue came in at $8.93 billion, up 20.5% year-over-year, outperforming Wall Street consensus by $30 million. Broadcom Inc. (NASDAQ:AVGO) also declared a $4.60 per share quarterly dividend, a 12.2% increase from its prior dividend of $4.10. The dividend was paid on December 30. The company announced that it would resume its authorized share repurchase programs for the remaining $13 billion.
On December 14, Deutsche Bank analyst Ross Seymore raised the firm's price target on Broadcom Inc. (NASDAQ:AVGO) to $590 from $575 and reiterated a Buy rating on the shares.
According to Insider Monkey’s third quarter database, Broadcom Inc. (NASDAQ:AVGO) was part of 74 hedge fund portfolios, compared to 66 in the earlier quarter. Ken Griffin’s Citadel Investment Group is a prominent stakeholder of the company, with 1.05 million shares worth $469 million.
Here is what Carillon Tower Advisers specifically said about Broadcom Inc. (NASDAQ:AVGO) in its Q2 2022 investor letter:
“Tech stocks, including Broadcom Inc. (NASDAQ:AVGO), were one of the hardest-hit sectors due to fears over a weakening macroeconomic environment. Broadcom, however, outperformed semiconductor peers as its end-market exposures provided relatively more defensive characteristics.”
9. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 75
Dividend Yield as of January 17: 1.25%
Eli Lilly and Company (NYSE:LLY) was founded in 1876 and is headquartered in Indianapolis, Indiana. The company discovers, develops, and markets human pharmaceuticals worldwide. On December 12, Eli Lilly and Company (NYSE:LLY) declared a $1.13 per share quarterly dividend, a 15.3% increase from its prior dividend of $0.98. The dividend is distributable on March 10, 2023 to shareholders of record on February 15. It is one of the best dividend stocks to invest in.
On January 3, investment advisory Barclays raised the firm's price target on Eli Lilly and Company (NYSE:LLY) to $400 from $395 and maintained an Overweight rating on the shares. Analyst Carter Gould issued the ratings update.
According to Insider Monkey’s data, 75 hedge funds were bullish on Eli Lilly and Company (NYSE:LLY) at the end of the third quarter of 2022, compared to 70 funds in the last quarter. Ken Fisher’s Fisher Asset Management is the largest stakeholder of the company, with 3.90 million shares valued at $1.26 billion.
Here is what ClearBridge Global Growth Strategy has to say about Eli Lilly and Company (NYSE:LLY) in its Q3 2022 investor letter:
“In the U.S., we initiated a position in pharmaceutical maker Eli Lilly (NYSE:LLY) as it brings out new drug candidates for diabetes and Alzheimer’s disease. New drugs impact diabetes but have also demonstrated significant weight loss for patients who are overweight and have other co-morbidity issues as a result. Lilly is one of the two key players in diabetes care and we believe the potential market opportunity is much higher than the consensus forecasts as we are seeing evidence of accelerating adoption.”
8. Exxon Mobil Corporation (NYSE:XOM)
Number of Hedge Fund Holders: 75
Dividend Yield as of January 17: 3.22%
Exxon Mobil Corporation (NYSE:XOM) is an American multinational producer of crude oil and natural gas in the United States and internationally. It operates through Upstream, Downstream, and Chemical segments. Exxon Mobil Corporation (NYSE:XOM)’s dividend payments to shareholders have grown at an average annual rate of 5.9% over the last 40 years, and it is one of the best dividend stocks to buy and hold. On January 13, Exxon Mobil Corporation (NYSE:XOM) announced that it would largely increase gasoline and diesel production at its Beaumont, Texas refinery, concluding a $1.2 billion expansion that was initially considered nine years ago. This would make the Beaumont refinery the second largest in the U.S.
On January 17, Scotiabank analyst Paul Cheng upgraded Exxon Mobil Corporation (NYSE:XOM) to Outperform from Sector Perform with a price target of $135, up from $120. He sees better cash flow generation from refining, which favors Exxon Mobil Corporation (NYSE:XOM) given that it has the highest refining exposure among the supermajors, the analyst told investors.
According to Insider Monkey’s data, Exxon Mobil Corporation (NYSE:XOM) was part of 75 hedge fund portfolios at the end of Q3 2022, compared to 72 funds in the prior quarter. Rajiv Jain’s GQG Partners is the leading position holder in the company, with 33.8 million shares worth nearly $3 billion.
In its Q2 2022 investor letter, First Eagle Investments, an asset management firm, highlighted a few stocks and Exxon Mobil Corporation (NYSE:XOM) was one of them. Here is what the fund said:
“Integrated oil and gas giant Exxon Mobil performed well in the second quarter as continued high prices for energy products supported the stock. As the largest refiner in the US, the company has benefitted from wide “crack spreads,” or the margin between the cost of crude oil and the petroleum products extracted from it. Exxon continues to invest in refining capacity in the US, which industry wide has been in steady decline since 2019. We are pleased that Exxon has been using its strong cash flows to reduce debt and to return cash to shareholders through dividends and stock repurchases.”
7. AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Holders: 80
Dividend Yield as of January 17: 3.85%
AbbVie Inc. (NYSE:ABBV) is an Illinois-based company that discovers, develops, manufactures, and sells pharmaceuticals worldwide. On October 28, AbbVie Inc. (NYSE:ABBV) declared a $1.48 per share quarterly dividend, a 5% increase from its prior dividend of $1.41. The dividend is distributable on February 15, 2023 to shareholders of record on January 3. AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks to consider for an income portfolio.
Truist analyst Robyn Karnauskas on January 5 raised the price target on AbbVie Inc. (NYSE:ABBV) to $180 from $160 and kept a Buy rating on the shares. The analyst cited accelerating prescription and share growth trends for Skyrizi and Rinvoq, as well as growth in Botox in the aesthetics mark for the target raise. The analyst raised her Skyrizi and Rinvoq numbers to better align with AbbVie Inc. (NYSE:ABBV)’s long-term outlook.
According to Insider Monkey’s data, 80 hedge funds were bullish on AbbVie Inc. (NYSE:ABBV) at the end of September 2022, compared to 71 funds in the last quarter. Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital is a significant position holder in the company, with 3.2 million shares worth $431.60 million.
Here is what Baron Funds specifically said about AbbVie Inc. (NYSE:ABBV) in its Q3 2022 investor letter:
“AbbVie Inc. (NYSE:ABBV) is a drug developer best known for Humira, an immunosuppressant that is the best selling drug of all time. Given outsized key product risk (patent cliff and generic launches beginning in 2023), AbbVie has broadened its pipeline, highlighted by its Allergan acquisition. Shares fell on results that missed consensus and indications that legacy franchises were outperforming newer product launches, calling into question AbbVie’s long-term strategy. With promising assets in the pipeline and its robust cash flow profile, we believe AbbVie will grow well into the future.”
6. Johnson & Johnson (NYSE:JNJ)
Number of Hedge Fund Holders: 85
Dividend Yield as of January 17: 2.61%
Johnson & Johnson (NYSE:JNJ) is an American multinational healthcare firm that has increased its dividend for the last 61 years, making it one of the best dividend stocks for a reliable income portfolio. On December 22, Johnson & Johnson (NYSE:JNJ) completed the acquisition of cardiac pump maker Abiomed, Inc. (NASDAQ:ABMD), for $16.6 billion in debt and cash. The transaction is expected to close in Q1 2023.
On December 12, Citi analyst Joanne Wuensch raised the firm's price target on Johnson & Johnson (NYSE:JNJ) to $205 from $198 and kept a Buy rating on the shares.
According to Insider Monkey’s data, 85 hedge funds were long Johnson & Johnson (NYSE:JNJ) at the end of Q3 2022, compared to 83 funds in the prior quarter. John Overdeck and David Siegel’s Two Sigma Advisors is the leading stakeholder of the company, with 3.11 million shares worth $509.30 million.
Like The Home Depot, Inc. (NYSE:HD), Mastercard Incorporated (NYSE:MA), and UnitedHealth Group Incorporated (NYSE:UNH), smart investors are piling into Johnson & Johnson (NYSE:JNJ) for a reliable income portfolio.
In its Q2 2022 investor letter, Mayar Capital, an asset management firm, highlighted a few stocks and Johnson & Johnson (NYSE:JNJ) was one of them. Here is what the fund said:
“Johnson & Johnson (NYSE:JNJ) is currently our largest position and a long-standing holding. The majority of the group’s sales comes from its collection of pharmaceutical franchises, but a large majority (~45%) comes from its collection of medical device businesses and its consumer brands.
Here’s how JNJ makes and spends a dollar of revenues: As of 2021, about 55 cents of that dollar comes from its pharmaceutical sales – sales of drugs to pharmacies and distributors – while 30 cents come from the sale of medical devices, such as surgery equipment and orthopedics. The rest of that dollar in sales comes from sales of JNJ’s consumer brands such as Listerine mouthwash, Nicorette nicotine tablets and Neutrogena cosmetics (…read more)
Click to continue reading and see 5 Best Dividend Stocks To Buy and Hold.
Suggested articles:
12 Best Holding Company Stocks To Invest In 12 Best Big Data Stocks To Buy 12 Biggest Ocean Cleaning Companies in the World
Disclosure: None. 14 Best Dividend Stocks To Buy and Hold is originally published on Insider Monkey.
- J&J completes $16.6B acquisition of local medical device firm
Dec 22, 2022
Johnson & Johnson Inc. closed its acquisition of Danvers medical device maker Abiomed Inc. on Thursday. The deal weighed in at $16.6 billion, making it easily one of the largest acquisitions of the year.
- 3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
Dec 22, 2022
Abiomed, Inc. ABMD is well-poised for growth in the coming quarters, backed by strength in its Impella product line. The optimism led by robust second-quarter fiscal 2023 performance along with positive tidings on the regulatory front are expected to contribute further. Headwinds from third-party reimbursement and forex woes persist.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 8.2% against 30% decline of the industry and 20.7% fall of the S&P 500 composite.
The renowned global provider of medical products designed to assist or replace the pumping function of the failing heart has a market capitalization of $17.18 billion. The company projects 25% growth for the next five years and expects to maintain its strong performance. It has delivered an earnings surprise of 15.6% for the past four quarters, on average. Zacks Investment Research
Image Source: Zacks Investment Research
Let’s delve deeper.
Strength in Impella: Abiomed’s flagship product line, Impella, has continued to be a growth driver, raising our optimism. The company is focused on achieving its Abiomed 2.0 goals, which will drive the rollout of its remote interface technology with SmartAssist and Impella Connect. Abiomed continues to invest in its pipeline of advanced technologies, including the XR Sheath, Impella ECP, Impella Connect, Impella BTR and new AI algorithms.
Regulatory Approvals: Abiomed has been riding on a suite of regulatory approvals of late, which raises our optimism. This month, the company announced that the FDA had approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, where the first two patients have been enrolled.
In October, Abiomed announced that Impella RP Flex with SmartAssist has received the FDA’s pre-market approval as safe and effective to treat acute right heart failure for up to 14 days.
Strong Q2 Results: Abiomed’s solid second-quarter fiscal 2023 earnings buoy optimism. The company saw a year-over-year uptick in the top and bottom lines, and continued strength in its global Impella revenues. Abiomed’s robust geographical performance is also encouraging.
Story continues
Downsides
Forex Woes: Abiomed’s reported sales and earnings are subject to fluctuations in foreign currency exchange rates because some of its international sales are denominated in local currencies and not in U.S. dollars. The company, at present, does not hedge its exposure to foreign currency fluctuations from international operations. Therefore, revenues and expenses denominated in foreign currencies may be translated into U.S. dollars at less favorable rates, resulting in reduced revenues and earnings.
Third-Party Reimbursement: Abiomed depends on third-party reimbursement to its customers for market acceptance of its products. Sales of medical devices largely depend on the reimbursement of patients’ medical expenses by government healthcare programs and private health insurers. Without government reimbursement or third-party insurers’ payments for patient care, the market for Abiomed’s products will be limited.
Estimate Trend
Abiomed is witnessing a negative estimate revision trend for fiscal 2023. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 3.9% south to $4.61.
The Zacks Consensus Estimate for the company’s third-quarter fiscal 2023 revenues is pegged at $293.2 million, suggesting a 12.3% improvement from the year-ago quarter’s reported number.
This compares to our third-quarter fiscal 2023 revenue estimate of $291.4 million, suggesting an 11.6% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Exact Sciences Corporation EXAS, ShockWave Medical, Inc. SWAV and Merit Medical Systems, Inc. MMSI.
Exact Sciences, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 27.5%. EXAS’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average beat being 0.6%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exact Sciences has lost 32.9% compared with the industry’s 23.7% decline in the past year.
ShockWave Medical, carrying a Zacks Rank #2 at present, has an estimated growth rate of 22.2% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 146.1%.
ShockWave Medical has gained 20.6% against the industry’s 30% decline over the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 10.6% against the industry’s 12.5% decline over the past year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
